Search | SciELO

RESUMO O DC de Neuroimunologia da ABN e o BCTRIMS trazem, nesse documento, as recomendações sobre vacinação da população com doenças desmielinizantes do sistema nervoso central (SNC) contra infecções em geral e contra o coronavírus da síndrome respiratória aguda grave 2 (SARS-CoV-2), causador da COVID-19. Destaca-se a gravidade do atual momento frente ao avanço da COVID-19 em nosso País, o que torna mais evidente e importante a criação de guia de referência para orientação aos médicos, pacientes e autoridades de saúde pública quanto à vacinação, meio efetivo e seguro no controle de determinadas doenças infecciosa. O DCNI/ABN e o BCTRIMS recomendam que os pacientes com doenças desmielinizantes do SNC (ex., EM e NMOSD) sejam constantemente monitorados, quanto a atualização do seu calendário vacinal, especialmente, no início ou antes da mudança do tratamento com uma droga modificadora de doença (DMD). É importante também salientar que as vacinas são seguras e os médicos devem estimular o seu uso em todos os pacientes. Evidentemente, deve ser dada especial atenção às vacinas com vírus vivos atenuados. Por fim, é importante que os médicos verifiquem qual DMD o paciente está em uso e quando foi feita a sua última dose, pois cada fármaco pode interagir de forma diferente com a indução da resposta imune.

ABSTRACT The Scientific Department of Neuroimmunology of the Brazilian Academy of Neurology (DCNI/ABN) and Brazilian Committee for Treatment and Research in Multiple Sclerosis and Neuroimmunological Diseases (BCTRIMS) provide recommendations in this document for vaccination of the population with demyelinating diseases of the central nervous system (CNS) against infections in general and against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes COVID-19. We emphasize the seriousness of the current situation in view of the spread of COVID-19 in our country. Therefore, reference guides on vaccination for clinicians, patients, and public health authorities are particularly important to prevent some infectious diseases. The DCNI/ABN and BCTRIMS recommend that patients with CNS demyelinating diseases (e.g., MS and NMOSD) be continually monitored for updates to their vaccination schedule, especially at the beginning or before a change in treatment with a disease modifying drug (DMD). It is also important to note that vaccines are safe, and physicians should encourage their use in all patients. Clearly, special care should be taken when live attenuated viruses are involved. Finally, it is important for physicians to verify which DMD the patient is receiving and when the last dose was taken, as each drug may affect the induction of immune response differently.

https://doi.org/10.1590/0004-282x-anp-2021-0162 1 downloads

Serological profile of John Cunningham virus (JCV) in patients with multiple sclerosis
Facebook Twitter

Other social networks
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Other networks

Metrics
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

Branco, Luciana Prats

; Adoni, Tarso

; Apostolos-Pereira, Samira Luisa

; Brooks, Joseph Bruno Bidin

; Correa, Eber Castro

; Damasceno, Carlos Augusto

; Eboni, Audred Cristina Biondo

; Fezer, Leticia

; Gama, Paulo Diniz da

; Goncalves, Marcus Vinicius Magno

; Gomes, Sidney

; Grzesiuk, Anderson Kuntz

; Mendes, Maria Fernanda

; Morales, Rogerio Rizo

; Muniz, Andre

; Parolin, Monica Fiuza Koncke

; Pimentel, Maria Lucia Vellutini

; Ribeiro, Marlise de Castro

; Santos, Gutemberg Augusto Cruz dos

; Sato, Henry Koiti

; Scherpenhuijzen, Simone Batista

; Scorcine, Claudio

; Siquineli, Fabio

; Sousa, Nise Alexandra de Carvalho

; Varela, Daniel Lima

; Winckler, Tereza Cristina Avila

; Fragoso, Yara Dadalti

Arquivos de Neuro-Psiquiatria

Journal Metrics
- Sobre o periódico
- SciELO Analytics

sep 2018, Volume 76 N. 9 Pages 588 - 591

Abstract: Pt En | Text: Pt En | PDF: Pt | PDF: En

RESUMO As opções terapêuticas para esclerose múltipla (EM) modificaram-se ao longo dos últimos anos, trazendo uma nova categoria de drogas com melhor perfil de eficácia. No entanto, estas drogas vieram com um novo perfil de potenciais eventos adversos que exigem que o neurologista os reconheça bem e rapidamente. Uma das complicações mais temidas destes tratamentos para a EM é a leucoencefalopatia multifocal progressiva (LEMP), causada pela reativação do vírus John Cunningham (JCV). Objetivo: Identificar o perfil sorológico de JCV em pacientes com EM. Métodos: Dados sorológicos de JCV foram obtidos através do ensaio por enzimas imuno-adsorvidas (ELISA) fornecido pelo programa STRATIFY-JCV. Resultados: Um total de 1.501 testes sanguíneos foram obtidos de 1.102 pacientes com EM. O grupo teve 633 pacientes (57,1%) soropositivos para anticorpos anti-JCV e 469 pacientes negativos (42,9%). Vinte e três pacientes se tornaram posivitos após resultados iniciais negativos para anticorpos anti-JCV. A taxa de soroconversão foi 18,5% em 22 meses. Conclusão: O perfil sorológico do JCV e a soroconversão nos pacientes brasileiros foi semelhante àquela descrita em outros países.

ABSTRACT Treatment options for multiple sclerosis (MS) have changed over the last few years, bringing about a new category of drugs with more efficient profiles. However, these drugs have come with a whole new profile of potential adverse events that neurologists have to learn well and quickly. One of the most feared complications of these MS treatments is progressive multifocal leukoencephalopathy caused by the reactivation of the John Cunningham virus (JCV). Objective: To identify the serologic profile of JCV in patients with MS. Methods: Data on serum antibodies for JCV were obtained using the enzyme-linked immunosorbent assay provided by the STRATIFY-JCV program. Results: A total of 1,501 blood tests were obtained from 1,102 patients with MS. There were 633 patients (57.1%) who were positive for antibodies for JCV and 469 patients who were negative (42.9%). Twenty-three patients became positive after initially having negative JCV antibody status. The rate of seroconversion was 18.5% over 22 months. Conclusion: The JCV serologic profile and seroconversion in Brazilian patients were similar to those described in other countries.

https://doi.org/10.1590/0004-282x20180083 3126 downloads

Olfactory dysfunction as a marker of multiple sclerosis progression
Facebook Twitter

Other social networks
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Other networks

Metrics
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

Pimentel, Maria Lucia Vellutini

Arquivos de Neuro-Psiquiatria

Journal Metrics
- Sobre o periódico
- SciELO Analytics

sep 2016, Volume 74 N. 9 Pages 693 - 694

Abstract: En | Text: En | PDF: En

https://doi.org/10.1590/0004-282X20160133 1486 downloads

Neuromyelitis optica spectrum disorder and Sjögren syndrome are overlapping disorders and participate in the same autoimmunity context?
Facebook Twitter

Other social networks
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Other networks

Metrics
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

Pimentel, Maria Lucia Vellutini

Arquivos de Neuro-Psiquiatria

Journal Metrics
- Sobre o periódico
- SciELO Analytics

aug 2014, Volume 72 N. 8 Pages 577 - 579

Abstract: En | Text: En | PDF: En

https://doi.org/10.1590/0004-282X20140115 2846 downloads

Multiple sclerosis in the Southern and Northern hemispheres: the month of birth at different latitudes has the same influence on the prevalence and progression of the disease in the Northern and Southern hemispheres?
Facebook Twitter

Other social networks
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Other networks

Metrics
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

Pimentel, Maria Lucia Vellutini

Arquivos de Neuro-Psiquiatria

Journal Metrics
- Sobre o periódico
- SciELO Analytics

sep 2013, Volume 71 N. 9A Pages 569 - 570

Abstract: En | Text: En | PDF: En

https://doi.org/10.1590/0004-282X20130114 3586 downloads

Natalizumab and multiple sclerosis
Facebook Twitter

Other social networks
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Other networks

Metrics
- SciELO Analytics
- Dimensions
- PlumX
- Altmetric

Pimentel, Maria Lucia Vellutini

Arquivos de Neuro-Psiquiatria

Journal Metrics
- Sobre o periódico
- SciELO Analytics

mar 2013, Volume 71 N. 3 Pages 135 - 136

Abstract: En | Text: En | PDF: En

https://doi.org/10.1590/S0004-282X2013000300001 2570 downloads

Immune system markers of neuroinflammation in patients with clinical diagnose of neuromyelitis optica
Facebook Twitter

Other social networks
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Other networks

Metrics
- SciELO Analytics

Alves-Leon, Soniza Vieira

; Pimentel, Maria Lucia Vellutini

; Sant'Anna, Gabrielle

; Malfetano, Fabíola Rachid

; Estrada, Cláudio Duque

; Quirico- Santos, Thereza

Arquivos de Neuro-Psiquiatria

Journal Metrics
- Sobre o periódico
- SciELO Analytics

2008, Volume 66 N. 3b Pages 678 - 684

Abstract: Pt En | Text: Pt En | PDF: Pt | PDF: En

A neuromielite óptica (NMO) é doença inflamatória do sistema nervoso central, caracterizada por mielite aguda ou subaguda grave e neurite óptica unilateral ou bilateral. Este estudo objetiva analisar parâmetros imunológicos de pacientes com critérios de Wingerchuck et al. (1999) para NMO. O método de ELISA avaliou a produção de IgG e IgA para antígenos da proteína básica da mielina (MBP), o proteolipídeo (PLP) 95-116, a glicoproteina associada ao oligodendrócito (MOG) 92-106 e as citocinas interleucina-4 (IL-4) e interferon-gama (INF-γ). Foram incluνdos 28 pacientes com NMO pareados com controles saudáveis. Pacientes com NMO apresentaram níveis significativamente elevados de imunoglobulinas reativas dos isotipos IgG para MOG (p<0,0001), PLP (p=0,0002) e MBP (p<0,0001) e IgA somente para MBP (p<0,0001). Os níveis de INF-γ (p=0,61) foram semelhantes aos controles. A produção elevada de IL-4 (p=0,0084) indica papel importante na ativação de células regulatórias Th2 e linfócitos B produtores de IgA e da ativação da imunidade humoral.

Neuromyelitis optica (NMO) is an inflammatory, demyelinating disease of the central nervous system characterized by the association of a serious myelitis and unilateral or bilateral optic neuritis. The present study aimed to analyze the immunological parameters of NMO patients with diagnosis established based on Wingerchuck et al. (1999) criteria. Production of IgG and IgA antibodies to antigens of MBP, PLP 95-116, MOG 92-106, and the cytokines interleukin-4 (IL-4) and interferon-γ (INF-γ) were assessed by Elisa assay. The cohort was formed by 28 NMO patients and a matched healthy control group. NMO patients had significant high levels of IgG to MOG (p<0.0001), PLP (p=0.0002) and MBP (p<0.0001), and solely IgA to MBP (p<0.0001). INF-γ (p=0.61) levels were similar to healthy controls. Increased production of IL-4 (p=0.0084) indicates an important role for this cytokine in the activation of Th2 regulatory cells and of the IgA producers B lymphocyte indicating activation of humoral immunity.

2975 downloads Cited 1 time in SciELO

Síndrome de Parinaud e sinal de Collier: manifestação neurológica inicial em paciente HIV-1 positivo
Facebook Twitter

Other social networks
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Other networks

Metrics
- SciELO Analytics

COSTA, MÔNICA FONSECA DA

; SANTOS, VALÉRIA

; PIMENTEL, MARIA LUCIA VELLUTINI

; NOVIS, SERGIO A. P.

Arquivos de Neuro-Psiquiatria

Journal Metrics
- Sobre o periódico
- SciELO Analytics

sep 1999, Volume 57 N. 3B Pages 876 - 880

Abstract: Pt En | Text: Pt En | PDF: Pt | PDF: En

Relatamos o terceiro caso da literatura de síndrome de Parinaud como manifestação clínica isolada de toxoplasmose mesencefálica em paciente HIV-1 positivo e revemos suas causas, enfatizando ser excepcional sua ocorrência por toxoplasmose cerebral. Destacamos a ocorrência isolada, sem associação de hidrocefalia obstrutiva e hipertensão intracraniana e chamamos atenção para o sinal de Collier insuficientemente conhecido, porém de grande relevância semiótica para lesão de localização mesencefálica.

We describe the third case in the literature of Parinaud`s syndrome as the sole manifestation of brainstem toxoplasmosis, in a positive HIV-1 patient and review the literature concerning the possible etiologies of Parinaud`s syndrome, enforcing that it is a rare manifestation of central nervous system toxoplasmosis. We refer to its occurrence without simultaneous obstructive hydrocephalus and increased intracranial pressure, pointing out the Collier signal which is not very well known, but has great semiotic value once it locates the lesion in the brainstem.

24909 downloads Cited 1 time in SciELO

Primary progressive freezing gait: case report
Facebook Twitter

Other social networks
Google+
LinkedIn
Reddit
StambleUpon
CiteULike
Mendeley
Other networks

Metrics
- SciELO Analytics

Nicaretta, Denise Hack

; Pereira, João Santos

; Pimentel, Maria Lucia Vellutini

Arquivos de Neuro-Psiquiatria

Journal Metrics
- Sobre o periódico
- SciELO Analytics

sep 1997, Volume 55 N. 3A Pages 496 - 498

Abstract: Pt En | Text: Pt En | PDF: Pt | PDF: En

Uma rara e distinta entidade neurológica, a marcha congelada progressiva primária, tem sido relatada na literatura. Descrevemos o caso de um paciente com este distúrbio da marcha que, apesar do longo curso da doença, não apresentava instabilidade postural. Como citado na literatura, a fisiopatologia desta condição permanece obscura, embora a falta de resposta à levodopa sugira uma possível participação de vias não dopaminérgicas. Alteração na percepção visual também pode estar envolvida na gênese desta afecção.

The clinical features of the primary progressive freezing gait, a rare and distinct neurological entity, have been described in some articles. This paper describes this gait disorder affecting one patient, whose condition's long course provoked no postural instability. As stated in the literature, the pathophysiology of the primary progressive freezing gait still remains unclear, although the lack of response to levodopa therapy suggests a possible involvement of nondopaminergic pathways. Alteration in the visual perception may be a potential cause for the condition.

1782 downloads Cited 1 time in SciELO

Showing

itens per page

Page of 1 Next

Select one or more results

All Alphabetic

Results

Comparative chart Download CSV

Statistics of

Send result

To*

Use ; (semicolon) to insert more emails.

Send to email

This page

Selected records

All references (max. 300)

Your email

Subject

Comments

Export format:

RIS (for EndNote, ProCite, Reference Manager, RefWorks, Citavi, etc.)

BibTeX

Citation

CSV (for Excel, etc)

Export:

This page

Selected itens

All references (max. 2000)

Sem resultados

No documents were found for your search

Glossary and search help

You can enrich your search in a very simple way. Use the search indexes combined with the connectors (AND or OR) and specify more your search.

For example, if you want to search for articles about
cases of dengue in Brasil in 2015, use:
ti:dengue and publication_year:2015 and aff_country:Brasil

See below the complete list of search indexes that can be used:

Index code	Element
ti	article title
au	author
kw	article keywords
subject	subject (title words, abstract and keywords)
ab	abstract
ta	journal short title (e.g. Cad. Saúde Pública)
journal_title	journal full title (e.g. Cadernos de Saúde Pública)
la	publication language code (e.g. pt - Portuguese, es - Spanish)
type	document type
pid	publication identifier
publication_year	publication year of publication
sponsor	sponsor
aff_country	country code of the author's affiliation
aff_institution	author affiliation institution
volume	article volume
issue	article issue
elocation	elocation
doi	DOI number
issn	journal ISSN
in	SciELO colection code (e.g. scl - Brasil, col - Colômbia)
use_license	article usage license code

SciELO - Scientific Electronic Library Online
Rua Dr. Diogo de Faria, 1087 – 9º andar – Vila Clementino 04037-003 São Paulo/SP - Brasil
Email: scielo@scielo.org

All the contents of this site www.scielo.br, except where otherwise noted, is licensed under a Creative Commons Attribution License.
more »